Polyendocrine Metabolic Ovarian Syndrome Disease Summary

Overview

Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovarian syndrome, is characterized by hormonal dysregulation that affects weight, metabolic and mental health, skin, and reproductive function. It is further discussed in the Introduction section. 

Polycystic ovarian syndrome affects approximately 6-21% of reproductive-aged women and is the most common cause of anovulatory infertility. A detailed discussion on the prevalence of polycystic ovarian syndrome is in the Epidemiology section.

The Pathophysiology section states that polycystic ovarian syndrome involves ovarian steroidogenesis and follicular development abnormalities. The developmental process and biochemical profile of polycystic ovarian syndrome are also discussed in this section.

The Risk Factors section enumerates the factors that influence the development of polycystic ovarian syndrome.

Polycystic Ovarian Syndrome_Disease Summary

History and Physical Examination

The Clinical Presentation section describes the signs and symptoms of patients with polycystic ovarian syndrome.

The History section focuses on the important information that should be asked in patients with polycystic ovarian syndrome, while the Physical Examination section discusses the features that should be observed in polycystic ovarian syndrome.

Diagnosis

The Diagnosis or Diagnostic Criteria section features the 2003 Rotterdam criteria and other guidelines criteria in the evaluation of patients with polycystic ovarian syndrome.

Discussion on blood tests that may be done in the diagnosis of polycystic ovarian syndrome is in the Laboratory Tests and Ancillaries section. 

The Imaging section explains the need for ultrasonography to evaluate patients with polycystic ovarian syndrome.

Other causes of amenorrhea that need to be considered and excluded in the diagnosis of polycystic ovarian syndrome are listed in the Differential Diagnosis section.

Management

The goals of pharmacological therapy in the management of polycystic ovarian syndrome are enumerated in the Principles of Therapy section.

The Pharmacological Therapy section discusses in detail the therapy options for polycystic ovarian syndrome depending on the clinical manifestations such as amenorrhea, excess androgen, and metabolic risks.

The Nonpharmacological section discusses the importance of lifestyle modification in the management of polycystic ovarian syndrome.

The Monitoring section explains the need for long-term follow-up depending on the associated conditions present in patients with polycystic ovarian syndrome.